UK’s NICE Slashes HTA Appraisal Time For Ngenla & Ofev Using New Approach
Ngenla and Ofev are the first two drugs to be evaluated using the health technology appraisal institute’s new proportionate approach – they were both appraised much faster than usual.
You may also be interested in...
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.